Individualized Stereotactic Ablative Radiotherapy for Lung Tumors

Дата публикации: 01-11-2023 00:00:00

This nonrandomized controlled trial of patients diagnosed with non–small cell lung cancer assesses whether individualizing stereotactic ablative radiotherapy dose and fractionation by tumor size, location, and histological characteristics may be associated with local tumor control and the rate of toxic effects.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer	0	14.28	01-01-2025
2	Rates of Systemic Treatment for Metastatic Non–Small Cell Lung Cancer Among Older Adults	0	5.92	01-07-2026
3	Transarterial Chemoembolization Plus Thermal Ablation in Unresectable Hepatocellular Carcinoma	0	5.96	30-07-2026
4	PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression	0	15.58	01-07-2026
5	Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk Breast Cancer	0	18.85	30-07-2026
6	PFS in Metastatic Breast Cancer by Local Investigators vs Blinded Independent Central Review	0	8.34	16-07-2026
7	Intraperitoneal and Intravenous Paclitaxel Plus S-1 for Gastric Cancer With Peritoneal Metastasis	0	4.7	01-07-2026
8	Long-Term Adverse Effects and Complications After Prostate Cancer Treatment	0	9.73	01-12-2024
9	Prostate Cancer Mortality After Relabeling Low-Grade Prostate Cancer as Precancerous	0	9.66	01-07-2026
10	Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC	0	5	30-06-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 6.6. Источник: archderm.jamanetwork.com.